home / stock / iva / iva articles

IVA Articles, Inventiva S.A.

Stock Information
Company Name: Inventiva S.A.
Stock Symbol: IVA
Market: NASDAQ
Website: inventivapharma.com
Menu
IVA IVA Quote IVA Short IVA News IVA Articles IVA Message Board
Get IVA Alerts

News, Short Squeeze, Breakout and More Instantly...
Inventiva announces a €20.1 million issuance of royalty certificates | Benzinga

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on futur...
Gold Falls Over 1%; HilleVax Shares Plunge | Benzinga

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite moving higher on Monday. The Dow traded down 0.12% to 39,329.47 while...

Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy t...

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position | Benzinga

Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 1...
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents | Benzinga

Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company foc...

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 | Benzinga

The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel...

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update | Benzinga

Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 20...
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH | Benzinga

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned r...

Why Is Inventiva's Stock Trading Higher on Monday? | Benzinga

Inventiva SA (NASDAQ:IVA) announced the publication in the peer-reviewed scientific journal Nature Communications of ...

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor | Benzinga

Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), ...
Next 10